ciprofloxacin has been researched along with Pneumonia in 99 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective, cost-effectiveness analysis was performed on 106 clinically evaluable patients who participated in a multi-centre, randomized study of sequential IV/oral ciprofloxacin therapy versus ceftazidime for the treatment of nosocomial pneumonia." | 9.08 | Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. ( Paladino, JA, 1995) |
| "Intravenous ciprofloxacin and ceftazidime were compared for efficacy in the treatment of nosocomial pneumonia and urinary tract infection (UTI)." | 9.07 | Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. ( Billeter, M; Dempsey, RJ; Hatton, J; Rapp, RP; Tibbs, PA; Young, AB, 1991) |
| "The efficacy and safety of oral temafloxacin (600 mg) and ciprofloxacin (500 mg) twice daily for seven days were compared in patients with mild to moderate lower respiratory tract infections." | 9.07 | Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study. ( Chodosh, S, 1991) |
| "Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia." | 9.07 | Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. ( Caldwell, JW; Fink, MP; Heard, SO; Johnson, RH; Leeper, KV; Niederman, MS; Schentag, JJ; Siami, GA; Snydman, DR; Wunderink, RG, 1994) |
| " Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of bronchopulmonary infections, a comparative trial of oral ciprofloxacin and intramuscular cefamandole was initiated in elderly patients with lower respiratory tract infections." | 9.06 | Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. ( Breitenbucher, R; Davies, S; Gruninger, R; Guay, DR; Logan, G; Obaid, S; Peterson, PK; Stein, D, 1988) |
| "A 77-year-old woman showed profound thrombocytopenia immediately after two ciprofloxacin injections for pneumonia." | 7.88 | Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin. ( Jeong, J; Koh, YI; Sim, DW; Yu, JE, 2018) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 7.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| " As far as we know, this is the first case of near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy patient." | 7.83 | Near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy white man: a case report. ( Cavallaro, MC; Chehter, N; Del Nero, LG; Marta, GN; Zambon, LS, 2016) |
| "Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for hospital-acquired (HAP) or nosocomial pneumonia." | 7.71 | [Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients]. ( Kljucar, S; Landen, H; Rost, KL, 2002) |
| "An experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats was used to study the impact of the duration of infection on the bactericidal activity of ceftazidime, gentamicin and ciprofloxacin." | 7.68 | Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1991) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 7.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "The use of ciprofloxacin as the sole agent in the treatment of 25 patients with pneumonias caused by susceptible organisms resulted in rapid cure." | 7.67 | Ciprofloxacin in the treatment of pneumonia. ( Colon-Lucca, H; Ernst, JA; Lorian, V; Rallos, T; Sandhu, N; Sy, ER, 1986) |
| "The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia." | 7.67 | Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986) |
| "Twenty-five acutely ill patients, 21 men and 4 women aged 20-90 years (mean, 54 years) with acute community-acquired bacterial pneumonia, were treated with ciprofloxacin orally." | 7.67 | Use of oral ciprofloxacin in community-acquired pneumonia. ( Bassaris, HP; Chrysanthopoulos, CJ, 1989) |
| "The therapeutic efficacy of ciprofloxacin, an investigational quinoline derivative, was compared with those of ticarcillin and tobramycin in guinea pigs with experimental Pseudomonas aeruginosa pneumonia." | 7.67 | Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. ( Pennington, JE; Schiff, JB; Small, GJ, 1984) |
| "The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 7.67 | Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
| "The antibacterial activities of ciprofloxacin versus ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 7.67 | Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
| "An experimental murine model of bacteraemic Haemophilus influenzae pneumonia was used to evaluate the therapeutic efficacy of ciprofloxacin, as compared with ampicillin and chloramphenicol." | 7.67 | Comparative efficacies of ciprofloxacin, ampicillin and chloramphenicol in treatment of experimental Haemophilus influenzae pneumonia. ( Borner, K; Kemmerich, B; Pennington, JE, 1987) |
| "Five hundred seventy-one patients with respiratory infections received orally administered ciprofloxacin (the majority received 600 mg daily)." | 6.66 | Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. ( Kobayashi, H, 1987) |
| "Telavancin displays potent in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to vancomycin." | 5.36 | Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. ( Crandon, JL; Kuti, JL; Nicolau, DP, 2010) |
| " Pharmacokinetic analysis in one patient treated with intravenous ciprofloxacin 300 mg showed that at 0." | 5.30 | The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections. ( Hiraga, Y; Ohmichi, M, 1999) |
| "The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats." | 5.28 | Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, BM; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1989) |
| "Interstitial nephritis is a rare but serious adverse effect of many drugs and usually is diagnosed by clinical signs and symptoms of hematuria, proteinuria, eosinophilia, fever, azotemia, and rash." | 5.28 | Suspected ciprofloxacin-induced interstitial nephritis. ( Murray, KM; Wilson, MG, 1990) |
| "Ciprofloxacin has been studied extensively in discriminative animal models of infection, and its efficacy in the treatment of these infections has been compared with that of standard therapy." | 5.27 | Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. ( Brooks-Fournier, RA; Gerberding, JL; Sande, MA, 1987) |
| "A retrospective, cost-effectiveness analysis was performed on 106 clinically evaluable patients who participated in a multi-centre, randomized study of sequential IV/oral ciprofloxacin therapy versus ceftazidime for the treatment of nosocomial pneumonia." | 5.08 | Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. ( Paladino, JA, 1995) |
| "Intravenous ciprofloxacin and ceftazidime were compared for efficacy in the treatment of nosocomial pneumonia and urinary tract infection (UTI)." | 5.07 | Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. ( Billeter, M; Dempsey, RJ; Hatton, J; Rapp, RP; Tibbs, PA; Young, AB, 1991) |
| "The efficacy and safety of oral temafloxacin (600 mg) and ciprofloxacin (500 mg) twice daily for seven days were compared in patients with mild to moderate lower respiratory tract infections." | 5.07 | Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study. ( Chodosh, S, 1991) |
| "Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia." | 5.07 | Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. ( Caldwell, JW; Fink, MP; Heard, SO; Johnson, RH; Leeper, KV; Niederman, MS; Schentag, JJ; Siami, GA; Snydman, DR; Wunderink, RG, 1994) |
| " Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of bronchopulmonary infections, a comparative trial of oral ciprofloxacin and intramuscular cefamandole was initiated in elderly patients with lower respiratory tract infections." | 5.06 | Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. ( Breitenbucher, R; Davies, S; Gruninger, R; Guay, DR; Logan, G; Obaid, S; Peterson, PK; Stein, D, 1988) |
| " We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre." | 3.88 | Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. ( Bishara, J; Gurion, R; Herscovici, C; Lahav, M; Magen, H; Moshe, M; Naparstek, E; Pasvolsky, O; Peck, A; Raanani, P; Rozovski, U; Sela-Navon, M; Shargian, L; Vaxman, I; Vidal, L; Wolach, O; Yahav, D; Yeshurun, M, 2018) |
| "A 77-year-old woman showed profound thrombocytopenia immediately after two ciprofloxacin injections for pneumonia." | 3.88 | Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin. ( Jeong, J; Koh, YI; Sim, DW; Yu, JE, 2018) |
| " As far as we know, this is the first case of near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy patient." | 3.83 | Near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy white man: a case report. ( Cavallaro, MC; Chehter, N; Del Nero, LG; Marta, GN; Zambon, LS, 2016) |
| " In experimental models of localized or disseminated bacterial and fungal infections, the sterically stabilized liposomes have successfully been used to improve antibiotic treatment using representative agents of various classes of antibacterial agents such as the beta-lactams, the aminoglycosides, and the quinolones or the antifungal agent amphotericin B." | 3.73 | Long-circulating sterically stabilized liposomes in the treatment of infections. ( Bakker-Woudenberg, IA; Becker, MJ; Guo, L; Schiffelers, RM; Storm, G, 2005) |
| "In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes." | 3.71 | Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. ( Bakker-Woudenberg, IA; Guo, L; Mouton, JW; ten Kate, MT; Working, P, 2002) |
| "Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for hospital-acquired (HAP) or nosocomial pneumonia." | 3.71 | [Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients]. ( Kljucar, S; Landen, H; Rost, KL, 2002) |
| "To determine the pharmacokinetic properties of ciprofloxacin in the critically ill, we studied seven mechanically ventilated patients with pneumonia during enteral feedings." | 3.69 | Enteric absorption of ciprofloxacin during tube feeding in the critically ill. ( Burns, GA; Cohn, SM; Milner, KA; Sawyer, MD; Tolomeo, C, 1996) |
| "An experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats was used to study the impact of the duration of infection on the bactericidal activity of ceftazidime, gentamicin and ciprofloxacin." | 3.68 | Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1991) |
| "Oral quinolones such as ciprofloxacin are promising agents in the treatment of serious bronchopulmonary infections due to susceptible gram-negative micro-organisms such as Haemophilus influenzae, Branhamella catarrhalis, Klebsiella pneumoniae and even Pseudomonas aeruginosa." | 3.67 | Role of fluoroquinolones in lower respiratory tract infections. ( Vellend, H, 1989) |
| "The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia." | 3.67 | Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986) |
| "The use of ciprofloxacin as the sole agent in the treatment of 25 patients with pneumonias caused by susceptible organisms resulted in rapid cure." | 3.67 | Ciprofloxacin in the treatment of pneumonia. ( Colon-Lucca, H; Ernst, JA; Lorian, V; Rallos, T; Sandhu, N; Sy, ER, 1986) |
| "The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 3.67 | Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
| "The antibacterial activities of ciprofloxacin versus ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared." | 3.67 | Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987) |
| "The therapeutic efficacy of ciprofloxacin, an investigational quinoline derivative, was compared with those of ticarcillin and tobramycin in guinea pigs with experimental Pseudomonas aeruginosa pneumonia." | 3.67 | Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. ( Pennington, JE; Schiff, JB; Small, GJ, 1984) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 3.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Twenty-five acutely ill patients, 21 men and 4 women aged 20-90 years (mean, 54 years) with acute community-acquired bacterial pneumonia, were treated with ciprofloxacin orally." | 3.67 | Use of oral ciprofloxacin in community-acquired pneumonia. ( Bassaris, HP; Chrysanthopoulos, CJ, 1989) |
| "An experimental murine model of bacteraemic Haemophilus influenzae pneumonia was used to evaluate the therapeutic efficacy of ciprofloxacin, as compared with ampicillin and chloramphenicol." | 3.67 | Comparative efficacies of ciprofloxacin, ampicillin and chloramphenicol in treatment of experimental Haemophilus influenzae pneumonia. ( Borner, K; Kemmerich, B; Pennington, JE, 1987) |
| "Ciprofloxacin therapy was well tolerated; ceftriaxone therapy was discontinued in two patients (8%) due to adverse reactions (intramuscular pain and drug fever)." | 2.67 | A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. ( Gruninger, RP; Guay, DR; Hirata-Dulas, CA; Peterson, PK; Stein, DJ, 1991) |
| "Five hundred seventy-one patients with respiratory infections received orally administered ciprofloxacin (the majority received 600 mg daily)." | 2.66 | Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. ( Kobayashi, H, 1987) |
| "Fifty-two patients with serious respiratory infections were treated with orally administered ciprofloxacin; 42 patients were evaluable for the efficacy analysis and all were evaluable for determining adverse reactions." | 2.66 | Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. ( Fass, RJ, 1987) |
| " The drug dosage was 300 mg every 12 hours in 19 patients and 200 mg intravenously every 12 hours in nine patients." | 2.66 | Treatment of serious infections with intravenous ciprofloxacin. ( Neu, HC; Scully, BE, 1987) |
| "Several new approaches to treatment of pneumonia in the critical care setting are being evaluated, including single-agent empiric coverage using a broad-spectrum beta-lactam agent; broad-spectrum quinolones, such as ciprofloxacin; intrabronchial aminoglycoside instillation therapy; and passive immune therapy with immunoglobulins and monoclonal antibodies." | 2.38 | Approach to therapy of respiratory infections in the critical care setting. ( Pennington, JE, 1990) |
| "aeruginosa-induced NET formation and lung inflammation." | 1.72 | CLEC5A is critical in Pseudomonas aeruginosa-induced NET formation and acute lung injury. ( Chiu, CH; Hsieh, SL; Peng, YC; Sung, PS; Yang, SP, 2022) |
| "Community-acquired pneumonia is associated with higher morbidity, hospitalization, and mortality in adults." | 1.72 | Bacterial profile, antimicrobial susceptibility patterns, and associated factors of community-acquired pneumonia among adult patients in Gondar, Northwest Ethiopia: A cross-sectional study. ( Assefa, M; Belachew, T; Tessema, B; Tigabu, A, 2022) |
| "Fluoroquinolones increase the risk of Clostridioides difficile infection and antibiotic resistance." | 1.51 | The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study. ( Chopra, V; Conlon, A; Flanders, SA; Gandhi, T; Malani, AN; Vaughn, VM, 2019) |
| " The poor solubility might lead to limited bioavailability and pharmacological action of the drug." | 1.48 | Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence of Size on Cellular Uptake. ( Costa, A; De Rossi, C; de Souza Carvalho-Wodarz, C; Ho, DK; Lehr, CM; Loretz, B, 2018) |
| "We present an interesting case of Legionnaires' disease masquerading as acute pyelonephritis, with complete absence of respiratory symptoms on admission." | 1.42 | A rare presentation of Legionnaires' disease. ( Banerjee, A; Delicata, M, 2015) |
| "Ciprofloxacin was associated with PRES in an adolescent male treated from chest infection." | 1.39 | Ciprofloxacin-associated posterior reversible encephalopathy. ( Ali, WH, 2013) |
| "Acute phlegmonous gastritis is an uncommon disease, often fatal condition characterized by suppurative bacterial infection of the gastric wall." | 1.37 | [A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone]. ( Kim, JS; Kim, NY; Lee, KJ; Park, JS; Yun, HK, 2011) |
| "Telavancin displays potent in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to vancomycin." | 1.36 | Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. ( Crandon, JL; Kuti, JL; Nicolau, DP, 2010) |
| "Pneumonia and acute respiratory distress syndrome are life-threatening complications after pneumonectomy carrying high mortality." | 1.32 | Successful therapy of severe pneumonia-associated ARDS after pneumonectomy with ECMO and steroids. ( Dünser, M; Hasibeder, W; Mayr, AJ; Rieger, M, 2004) |
| " Pharmacokinetic analysis in one patient treated with intravenous ciprofloxacin 300 mg showed that at 0." | 1.30 | The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections. ( Hiraga, Y; Ohmichi, M, 1999) |
| " The pharmacokinetic profile of the drug was then superimposed on the bacterial MIC, and we then derived the patients individual peak to MIC ratio, area above MIC, and time above MIC." | 1.28 | Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. ( Schentag, JJ, 1990) |
| "Ciprofloxacin treatment was effective on both occasions." | 1.28 | Successful treatment of Bacillus cereus infection with ciprofloxacin. ( Gascoigne, AD; Gibson, GJ; Gould, K; Richards, J, 1991) |
| "Fleroxacin was inactive against S." | 1.28 | In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. ( Beskid, G; Chan, K; Cleeland, R; Keith, DD; McGarry, CM; Siebelist, J, 1990) |
| "Interstitial nephritis is a rare but serious adverse effect of many drugs and usually is diagnosed by clinical signs and symptoms of hematuria, proteinuria, eosinophilia, fever, azotemia, and rash." | 1.28 | Suspected ciprofloxacin-induced interstitial nephritis. ( Murray, KM; Wilson, MG, 1990) |
| "The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats." | 1.28 | Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, BM; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1989) |
| "Ciprofloxacin has been studied extensively in discriminative animal models of infection, and its efficacy in the treatment of these infections has been compared with that of standard therapy." | 1.27 | Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. ( Brooks-Fournier, RA; Gerberding, JL; Sande, MA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (24.24) | 18.7374 |
| 1990's | 31 (31.31) | 18.2507 |
| 2000's | 18 (18.18) | 29.6817 |
| 2010's | 22 (22.22) | 24.3611 |
| 2020's | 4 (4.04) | 2.80 |
| Authors | Studies |
|---|---|
| Crandon, JL | 1 |
| Kuti, JL | 1 |
| Nicolau, DP | 2 |
| Assefa, M | 1 |
| Tigabu, A | 1 |
| Belachew, T | 1 |
| Tessema, B | 1 |
| Sung, PS | 1 |
| Peng, YC | 1 |
| Yang, SP | 1 |
| Chiu, CH | 1 |
| Hsieh, SL | 1 |
| Rashid, F | 1 |
| Pervaiz, I | 1 |
| Malik, H | 1 |
| Kanwal, Z | 1 |
| Rafique, M | 1 |
| Gillani, SSA | 1 |
| Liu, X | 1 |
| Xiang, L | 1 |
| Yin, Y | 1 |
| Li, H | 1 |
| Ma, D | 1 |
| Qu, Y | 1 |
| Ferrone, V | 2 |
| Carlucci, M | 2 |
| Cotellese, R | 2 |
| Raimondi, P | 2 |
| Cichella, A | 2 |
| Di Marco, L | 1 |
| Genovese, S | 1 |
| Carlucci, G | 2 |
| Sim, DW | 1 |
| Yu, JE | 1 |
| Jeong, J | 1 |
| Koh, YI | 1 |
| Goodlet, KJ | 1 |
| Nailor, MD | 1 |
| Hsu, CY | 1 |
| Sung, CT | 1 |
| Aljuffali, IA | 1 |
| Chen, CH | 1 |
| Hu, KY | 1 |
| Fang, JY | 1 |
| Yeshurun, M | 1 |
| Vaxman, I | 1 |
| Shargian, L | 1 |
| Yahav, D | 1 |
| Bishara, J | 1 |
| Pasvolsky, O | 1 |
| Wolach, O | 1 |
| Lahav, M | 1 |
| Gurion, R | 1 |
| Magen, H | 1 |
| Vidal, L | 1 |
| Herscovici, C | 1 |
| Peck, A | 1 |
| Moshe, M | 1 |
| Sela-Navon, M | 1 |
| Naparstek, E | 1 |
| Raanani, P | 1 |
| Rozovski, U | 1 |
| Ho, DK | 1 |
| Costa, A | 1 |
| De Rossi, C | 1 |
| de Souza Carvalho-Wodarz, C | 1 |
| Loretz, B | 1 |
| Lehr, CM | 1 |
| Rahdar, HA | 1 |
| Kazemian, H | 1 |
| Bimanand, L | 1 |
| Shahraki-Zahedani, S | 1 |
| Feyisa, SG | 1 |
| Taki, E | 1 |
| Havaei, SA | 1 |
| Karami-Zarandi, M | 1 |
| Wang, YC | 1 |
| Huang, TW | 1 |
| Yang, YS | 1 |
| Kuo, SC | 1 |
| Chen, CT | 1 |
| Liu, CP | 1 |
| Liu, YM | 1 |
| Chen, TL | 1 |
| Chang, FY | 1 |
| Wu, SH | 1 |
| How, CK | 1 |
| Lee, YT | 1 |
| Taniwaki, M | 1 |
| Katsutani, S | 1 |
| Yamasaki, M | 1 |
| Kawamoto, K | 1 |
| Funaishi, K | 1 |
| Matsumoto, Y | 1 |
| Matsumoto, N | 1 |
| Ohashi, N | 1 |
| Hattori, N | 1 |
| Vaughn, VM | 1 |
| Gandhi, T | 1 |
| Conlon, A | 1 |
| Chopra, V | 1 |
| Malani, AN | 1 |
| Flanders, SA | 1 |
| Ali, WH | 1 |
| Lee, SH | 1 |
| Teo, J | 1 |
| Heng, D | 1 |
| Zhao, Y | 1 |
| Ng, WK | 1 |
| Chan, HK | 1 |
| Tan, RB | 1 |
| Bruin, JP | 1 |
| Koshkolda, T | 1 |
| IJzerman, EP | 1 |
| Lück, C | 1 |
| Diederen, BM | 1 |
| Den Boer, JW | 1 |
| Mouton, JW | 2 |
| Delicata, M | 1 |
| Banerjee, A | 1 |
| Stiefelhagen, P | 1 |
| Zambon, LS | 1 |
| Marta, GN | 1 |
| Chehter, N | 1 |
| Del Nero, LG | 1 |
| Cavallaro, MC | 1 |
| Zycinska, K | 1 |
| Chmielewska, M | 1 |
| Lenartowicz, B | 1 |
| Hadzik-Blaszczyk, M | 1 |
| Cieplak, M | 1 |
| Kur, Z | 1 |
| Krupa, R | 1 |
| Wardyn, KA | 1 |
| Gal, Y | 1 |
| Sapoznikov, A | 1 |
| Falach, R | 1 |
| Ehrlich, S | 1 |
| Aftalion, M | 1 |
| Sabo, T | 1 |
| Kronman, C | 1 |
| Marco, LD | 1 |
| Sibila, O | 1 |
| Luna, CM | 1 |
| Agustí, C | 1 |
| Baquero, S | 1 |
| Gando, S | 1 |
| Patrón, JR | 1 |
| Morato, JG | 1 |
| Absi, R | 1 |
| Bassi, N | 1 |
| Torres, A | 1 |
| Mizell, KN | 1 |
| Patterson, KV | 1 |
| Carter, JE | 1 |
| Loriot, Y | 1 |
| Ferte, C | 1 |
| Gomez-Roca, C | 1 |
| Moldovan, C | 1 |
| Bahleda, R | 1 |
| Wislez, M | 1 |
| Cadranel, J | 1 |
| Soria, JC | 1 |
| Kim, NY | 1 |
| Park, JS | 1 |
| Lee, KJ | 1 |
| Yun, HK | 1 |
| Kim, JS | 1 |
| López-Rojas, R | 1 |
| Sánchez-Céspedes, J | 1 |
| Docobo-Pérez, F | 1 |
| Domínguez-Herrera, J | 1 |
| Vila, J | 1 |
| Pachón, J | 1 |
| Bakker-Woudenberg, IA | 6 |
| ten Kate, MT | 1 |
| Guo, L | 2 |
| Working, P | 1 |
| Kljucar, S | 1 |
| Rost, KL | 1 |
| Landen, H | 1 |
| Dünser, M | 1 |
| Hasibeder, W | 1 |
| Rieger, M | 1 |
| Mayr, AJ | 1 |
| Schiffelers, RM | 1 |
| Storm, G | 1 |
| Becker, MJ | 1 |
| Lishmanov, YB | 1 |
| Sazonova, SI | 1 |
| Sokolovich, EG | 1 |
| Chernov, VI | 1 |
| Dareau, S | 1 |
| Eledjam, JJ | 1 |
| Gros, T | 1 |
| Delire, V | 1 |
| Causse, L | 1 |
| Javitary, W | 1 |
| Bassoul, B | 1 |
| Patel, SM | 1 |
| Saravolatz, LD | 1 |
| Chono, S | 1 |
| Tanino, T | 1 |
| Seki, T | 1 |
| Morimoto, K | 1 |
| Schiff, JB | 1 |
| Small, GJ | 2 |
| Pennington, JE | 4 |
| de la Fuente, J | 1 |
| Albo, C | 1 |
| Rodríguez, A | 1 |
| Sopeña, B | 1 |
| Martínez, C | 1 |
| Fink, MP | 1 |
| Snydman, DR | 1 |
| Niederman, MS | 1 |
| Leeper, KV | 1 |
| Johnson, RH | 1 |
| Heard, SO | 1 |
| Wunderink, RG | 1 |
| Caldwell, JW | 1 |
| Schentag, JJ | 2 |
| Siami, GA | 1 |
| Bick, JA | 1 |
| Semel, JD | 1 |
| de Man, RA | 1 |
| Hilvering, C | 1 |
| Groen, HJ | 1 |
| Balk, AH | 1 |
| Snydman, D | 1 |
| Fink, M | 1 |
| Niederman, M | 1 |
| Reinhart, H | 1 |
| Cornelissen, JJ | 1 |
| Rozenberg-Arska, M | 1 |
| Dekker, AW | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Cohn, SM | 1 |
| Sawyer, MD | 1 |
| Burns, GA | 1 |
| Tolomeo, C | 1 |
| Milner, KA | 1 |
| Brouwers, PJ | 1 |
| de Boer, LE | 1 |
| Guchelaar, HJ | 1 |
| Lingnau, W | 1 |
| Berger, J | 1 |
| Javorsky, F | 1 |
| Lejeune, P | 1 |
| Mutz, N | 1 |
| Benzer, H | 1 |
| Paladino, JA | 1 |
| Ohmichi, M | 1 |
| Hiraga, Y | 1 |
| Singh, N | 1 |
| Rogers, P | 1 |
| Atwood, CW | 1 |
| Wagener, MM | 1 |
| Yu, VL | 1 |
| Ghosh, SK | 1 |
| Sundram, FX | 1 |
| Wong, WY | 1 |
| Ang, ES | 1 |
| Goh, AS | 1 |
| Ng, DC | 1 |
| Yu, S | 1 |
| Milkovich, G | 1 |
| Stewart, JM | 1 |
| Quirk, JR | 1 |
| Wiadrowski, TP | 1 |
| Reid, CM | 1 |
| Bauwens, JE | 1 |
| Spach, DH | 1 |
| Schacker, TW | 1 |
| Mustafa, MM | 1 |
| Bowden, RA | 1 |
| Barrie, JR | 1 |
| Mousdale, S | 1 |
| Chodosh, S | 1 |
| Kosmidis, J | 1 |
| Beskid, G | 2 |
| Albrecht, HA | 1 |
| Fallat, V | 1 |
| Keith, DD | 2 |
| Lipschitz, ER | 1 |
| McGarry, CM | 2 |
| McGarry, DH | 1 |
| Rossman, P | 1 |
| Siebelist, J | 2 |
| Roosendaal, R | 4 |
| van den Berghe-van Raffe, M | 4 |
| Vink-van den Berg, JC | 4 |
| Michel, MF | 3 |
| Thys, JP | 1 |
| Jacobs, F | 1 |
| Byl, B | 1 |
| Gascoigne, AD | 1 |
| Richards, J | 1 |
| Gould, K | 1 |
| Gibson, GJ | 1 |
| Yoshikawa, TT | 1 |
| Hirata-Dulas, CA | 1 |
| Stein, DJ | 1 |
| Guay, DR | 2 |
| Gruninger, RP | 1 |
| Peterson, PK | 2 |
| Kikuchi, N | 1 |
| Kawashima, T | 1 |
| Yamagishi, F | 1 |
| Suzuki, K | 1 |
| Yasuda, J | 1 |
| Niijima, Y | 1 |
| Mizutani, F | 1 |
| Tabeta, H | 1 |
| Rapp, RP | 1 |
| Billeter, M | 1 |
| Hatton, J | 1 |
| Young, AB | 1 |
| Tibbs, PA | 1 |
| Dempsey, RJ | 1 |
| Cleeland, R | 1 |
| Chan, K | 1 |
| Lode, H | 1 |
| Wiley, E | 1 |
| Olschewski, P | 1 |
| Sievers, H | 1 |
| Wintermantel, M | 1 |
| Baetz, R | 1 |
| Lebahn, K | 1 |
| Reinke, M | 1 |
| Wagner, J | 1 |
| Borner, K | 2 |
| Murray, KM | 1 |
| Wilson, MG | 1 |
| Loos, U | 1 |
| Marklein, G | 1 |
| Scholl, H | 1 |
| Schwabe, HK | 1 |
| Gordon, JJ | 1 |
| Kauffman, CA | 1 |
| Michel, BM | 1 |
| Andriole, VT | 1 |
| Chrysanthopoulos, CJ | 1 |
| Bassaris, HP | 1 |
| Scully, BE | 2 |
| Neu, HC | 2 |
| Parry, MF | 1 |
| Mandell, W | 1 |
| Altés, J | 1 |
| Gascó, J | 1 |
| de Antonio, J | 1 |
| Salas, A | 1 |
| Villalonga, C | 1 |
| Vellend, H | 1 |
| Klesel, N | 1 |
| Limbert, M | 1 |
| Seibert, G | 1 |
| Winkler, I | 1 |
| Schrinner, E | 1 |
| Kemmerich, B | 2 |
| Finch, R | 1 |
| Whitby, M | 1 |
| Craddock, C | 1 |
| Holliday, A | 1 |
| Martin, J | 1 |
| Pilkington, R | 1 |
| Hirai, K | 1 |
| Aoyama, H | 1 |
| Hosaka, M | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Ernst, JA | 1 |
| Sy, ER | 1 |
| Colon-Lucca, H | 1 |
| Sandhu, N | 1 |
| Rallos, T | 1 |
| Lorian, V | 1 |
| Stein, D | 1 |
| Logan, G | 1 |
| Obaid, S | 1 |
| Gruninger, R | 1 |
| Davies, S | 1 |
| Breitenbucher, R | 1 |
| Gordin, FM | 1 |
| Hackbarth, CJ | 1 |
| Scott, KG | 1 |
| Sande, MA | 2 |
| van den Broek, PJ | 1 |
| Bakker, W | 1 |
| Mattie, H | 1 |
| van Gulpen, C | 1 |
| Wollschlager, CM | 1 |
| Raoof, S | 1 |
| Khan, FA | 1 |
| Kobayashi, H | 1 |
| Fass, RJ | 1 |
| Brooks-Fournier, RA | 1 |
| Gerberding, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome[NCT01423864] | Phase 2 | 29 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation[NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to NIAID terminated the study due to low subject enrollment) | ||
| Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Reduction of the Duration of Antibiotic Guided by Procalcitonin in Infections Lungs of Hospitalized Elderly: a Randomized[NCT02173613] | 117 participants (Actual) | Interventional | 2012-08-31 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| MEGroup - Meropenem Only | 8 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 8 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 2 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 0 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 3 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 9 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 11 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment
| Intervention | participants (Number) | |
|---|---|---|
| suppression of emergence of resistance | emergence of resistance | |
| I.V. Meropenem | 5 | 1 |
5 reviews available for ciprofloxacin and Pneumonia
| Article | Year |
|---|---|
Community Acquired Pseudomonas Aeruginosa Pneumonia in a Young Athlete Man: A Case Report and Literature Review.
Topics: Adult; Athletes; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Fatal Outcome; Femal | 2018 |
Empyema necessitatis due to methicillin-resistant Staphylococcus aureus: case report and review of the literature.
Topics: Anti-Bacterial Agents; Blood; Ciprofloxacin; Empyema; Humans; Lung; Male; Methicillin Resistance; Mi | 2008 |
Monotherapy versus combination therapy.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Cellulit | 2006 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
Approach to therapy of respiratory infections in the critical care setting.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Humans; Inte | 1990 |
18 trials available for ciprofloxacin and Pneumonia
| Article | Year |
|---|---|
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin | 1994 |
Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin.
Topics: Aged; Anti-Infective Agents; APACHE; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxaci | 1995 |
Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fever of Unknown | 1995 |
Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Translocation; Ciprof | 1997 |
Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Canada; Ceftazidime; Ci | 1995 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Evaluation of technetium-99m ciprofloxacin (Infecton) in the imaging of infection.
Topics: Abscess; Adult; Aged; Bacterial Infections; Ciprofloxacin; Evaluation Studies as Topic; Female; Huma | 2000 |
Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study.
Topics: Ambulatory Care; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones | 1991 |
A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections.
Topics: Adolescent; Adult; Anti-Infective Agents; Bronchitis; Ciprofloxacin; Double-Blind Method; Female; Fl | 1991 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchitis; Ceftriaxone; Ciprofloxacin; Cross Infecti | 1991 |
[Clinical evaluation of ciprofloxacin in pulmonary infections in the patients with chronic respiratory diseases].
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pneumonia; Respirato | 1991 |
Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection.
Topics: Adult; Ceftazidime; Ciprofloxacin; Cross Infection; Double-Blind Method; Drug Evaluation; Humans; Pn | 1991 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchitis; Cefamandole; Ciprofloxacin; Clinical Tria | 1988 |
Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Clinical Trials as Topic; Diges | 1987 |
Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Bronchitis; Ciprofloxacin; Clinical Trials | 1987 |
Treatment of serious infections with intravenous ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Arthritis, Infectious; Bacterial Infections; Ciprofloxacin; Clini | 1987 |
77 other studies available for ciprofloxacin and Pneumonia
| Article | Year |
|---|---|
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Lipoglycopeptides; | 2010 |
Bacterial profile, antimicrobial susceptibility patterns, and associated factors of community-acquired pneumonia among adult patients in Gondar, Northwest Ethiopia: A cross-sectional study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Community-Acquired I | 2022 |
CLEC5A is critical in Pseudomonas aeruginosa-induced NET formation and acute lung injury.
Topics: Acute Lung Injury; Animals; Caspases; Ciprofloxacin; Cytokines; Lectins, C-Type; Lipopolysaccharides | 2022 |
Investigations on Synergistic and Antioxidant Actions of Medicinal Plant- Based Biosynthesis of Zinc Oxide Nanoparticles Against E.coli and K. pneumonia Bacteria.
Topics: Anti-Bacterial Agents; Antioxidants; Bacteria; beta-Lactams; Ciprofloxacin; Escherichia coli; Metal | 2022 |
Pneumonia caused by Pseudomonas fluorescens: a case report.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Humans; Lung; Male; Microbial Sensitivity Tests; Pneumon | 2021 |
Development of a dried blood spot HPLC-PDA method for the analysis of linezolid and ciprofloxacin in hospital-acquired pneumonia patients.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Dried B | 2017 |
Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Gemifloxacin; Humans; Naphthyr | 2018 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug | 2017 |
Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia.
Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Male; Methicil | 2018 |
Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Controlled Be | 2018 |
Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence of Size on Cellular Uptake.
Topics: Anti-Bacterial Agents; Biological Availability; Cell Line, Tumor; Cell Membrane Permeability; Ciprof | 2018 |
Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Biofil | 2018 |
Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report.
Topics: Aged; Anti-Bacterial Agents; Antibody Specificity; Antifungal Agents; Autoantibodies; Autoimmune Dis | 2019 |
The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Ciprofloxacin; Clostridium Infections; Cohor | 2019 |
Ciprofloxacin-associated posterior reversible encephalopathy.
Topics: Adolescent; Anti-Infective Agents; Ciprofloxacin; Humans; Magnetic Resonance Imaging; Male; Pneumoni | 2013 |
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Beclomethasone; Ciprofloxac | 2014 |
Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Hu | 2014 |
A rare presentation of Legionnaires' disease.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Ciprofloxacin; Community-Acquired Infections; Diagnosis, | 2015 |
[Suspected severe pneumonia. Antibiotics are ineffective - what now?].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Cyclophosphamide; Diagnosis, Differential; | 2015 |
Near-drowning-associated pneumonia with bacteremia caused by coinfection with methicillin-susceptible Staphylococcus aureus and Edwardsiella tarda in a healthy white man: a case report.
Topics: Adult; Bacteremia; Ceftriaxone; Ciprofloxacin; Clindamycin; Coinfection; Edwardsiella tarda; Enterob | 2016 |
Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection.
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Ciprofloxacin; | 2016 |
Potent Antiedematous and Protective Effects of Ciprofloxacin in Pulmonary Ricinosis.
Topics: Administration, Intranasal; Animals; Antitoxins; Ciprofloxacin; Cytokines; Female; Immunologic Facto | 2016 |
Development and validation of a fast micro-extraction by packed sorbent UHPLC-PDA method for the simultaneous determination of linezolid and ciprofloxacin in human plasma from patients with hospital-acquired pneumonia.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Electrical Equipment and Suppl | 2017 |
Effects of glucocorticoids in ventilated piglets with severe pneumonia.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoalveolar Lavage; Ciprofloxacin; Diseas | 2008 |
Pemetrexed-induced pneumonitis: a case report.
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Antineoplastic Agents; Carcinoma, Non-Small-Ce | 2009 |
[A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone].
Topics: Acinetobacter; Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Ceftri | 2011 |
Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Infective Agents; Blood Bactericida | 2011 |
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Topics: Acute Disease; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Progression; | 2002 |
[Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients].
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Germany; Humans; I | 2002 |
Moxifloxacin: new preparation. A me-too with more cardiac risks.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Approval; Fluoroquinolones; France | 2002 |
Successful therapy of severe pneumonia-associated ARDS after pneumonectomy with ECMO and steroids.
Topics: Anti-Inflammatory Agents; Bronchial Fistula; Carcinoma, Bronchogenic; Cilastatin; Ciprofloxacin; Com | 2004 |
Long-circulating sterically stabilized liposomes in the treatment of infections.
Topics: Ammonium Sulfate; Amphotericin B; Animals; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Drug C | 2005 |
Comparative scintigraphic study of 99mTc ciprofloxacin pharmacokinetics after intravenous and lymphotropic administration in experimental pulmonary suppuration.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dogs; Female; Injections, Intravenous; Lung; Lymphati | 2005 |
[Postoperative pneumonia: nosocomial, predictable, iatrogenic, preventable or not?].
Topics: Alcoholism; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Carcinoma, Squamo | 2006 |
Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Liposomes; Lung; Macrophages, Alveolar; Ma | 2008 |
Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Guinea Pigs; Kinetics; Pneumonia; Pseudomonas aerugin | 1984 |
Bordetella bronchiseptica pneumonia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Bordetella bronchi | 1994 |
Fulminant community-acquired Acinetobacter pneumonia in a healthy woman.
Topics: Acinetobacter calcoaceticus; Acinetobacter Infections; Aged; Ciprofloxacin; Drug Resistance, Microbi | 1993 |
[Nocardiosis: a treacherous generalized infection].
Topics: Aged; Amikacin; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nocardi | 1993 |
Avoiding adverse reactions.
Topics: Antacids; Anti-Infective Agents; Asthma; Bronchodilator Agents; Ciprofloxacin; Drug Interactions; Hu | 1996 |
Enteric absorption of ciprofloxacin during tube feeding in the critically ill.
Topics: Adult; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Critical Illness; Enteral Nutrition; Fema | 1996 |
Ciprofloxacin-phenytoin interaction.
Topics: Aged; Anti-Infective Agents; Anticonvulsants; Ciprofloxacin; Drug Interactions; Humans; Male; Phenyt | 1997 |
The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchiolitis; Ciprofloxacin; Female; Humans; In | 1999 |
A rare infection caused by Chryseomonas luteola.
Topics: Adult; Anti-Infective Agents; Anti-Infective Agents, Local; Chlorhexidine; Ciprofloxacin; Diabetes C | 2000 |
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Topics: Administration, Oral; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Community-Acquired Infecti | 2001 |
Community-acquired pneumonia caused by Enterobacter asburiae.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Enterobacteriaceae Infec | 2001 |
Drug-induced linear IgA bullous disease following antibiotics.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Arm; Ciprofloxacin; Drug Eruptions; Endocarditis | 2001 |
Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation.
Topics: Adult; Bacteremia; Bone Marrow Transplantation; Bordetella bronchiseptica; Bordetella Infections; Ci | 1992 |
Ciprofloxacin levels in a patient undergoing veno-venous haemodiafiltration.
Topics: Acute Kidney Injury; Adult; Chromatography, High Pressure Liquid; Ciprofloxacin; Dialysis Solutions; | 1992 |
In vitro and in vivo activity of carbamate-linked dual-action antibacterial Ro 24-4383.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Ciprofloxacin; Gram-Negative Bacteria; Gram-Positive Bac | 1991 |
Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.
Topics: Animals; Bacteremia; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Administration Schedul | 1991 |
Successful treatment of Bacillus cereus infection with ciprofloxacin.
Topics: Adult; Bacillus cereus; Ciprofloxacin; Humans; Male; Pneumonia; Sepsis | 1991 |
Treatment of nursing home-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Cross Infection; Homes for the Aged; Humans | 1991 |
Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Cefmenoxime; Ciprofloxacin; Cross Infection; Female; | 1990 |
In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Drug Evaluation, Pr | 1990 |
Suspected ciprofloxacin-induced interstitial nephritis.
Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Ciprofloxacin; Creatinine; Female; Humans; Kidney Func | 1990 |
[Bronchopulmonary penetration of ciprofloxacin].
Topics: Bacterial Infections; Bronchi; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Humans; Macrophages; Pne | 1990 |
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumonia; Pneumonia, Pneumococcal; Pseudomonas Infections | 1990 |
Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Female; Ge | 1989 |
An update on the efficacy of ciprofloxacin in animal models of infection.
Topics: Abscess; Animals; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Endocarditis, Bacteri | 1989 |
Use of oral ciprofloxacin in community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Admi | 1989 |
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary | 1986 |
Ciprofloxacin and delirium.
Topics: Acquired Immunodeficiency Syndrome; Ciprofloxacin; Delirium; Humans; Male; Middle Aged; Pneumonia | 1989 |
Role of fluoroquinolones in lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bronchi; Bronchitis; Ciprofloxacin; Cystic Fibrosis; Gram-Negative B | 1989 |
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Klebsiell | 1986 |
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Guinea Pigs; Kinetics; Naphthyridines; Oflo | 1986 |
Clinical evaluation of treatment with ciprofloxacin.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; | 1986 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
Ciprofloxacin in the treatment of pneumonia.
Topics: Adult; Aged; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumoni | 1986 |
Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.
Topics: Agranulocytosis; Animals; Anti-Bacterial Agents; Ciprofloxacin; Guinea Pigs; Half-Life; Microbial Se | 1985 |
Acute respiratory insufficiency from psittacosis.
Topics: Acute Disease; Adult; Ciprofloxacin; Female; Humans; Middle Aged; Pneumonia; Psittacosis; Quinolines | 1985 |
Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.
Topics: Animals; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Female; Klebsiella Infections; Kl | 1987 |
Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.
Topics: Animals; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Klebsiella Infections; Klebsiella | 1987 |
The use of ciprofloxacin in the treatment of patients with cystic fibrosis.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Haemophilus | 1987 |
Oral ciprofloxacin in the treatment of 14 patients with bacterial pneumonia.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle | 1987 |
Comparative efficacies of ciprofloxacin, ampicillin and chloramphenicol in treatment of experimental Haemophilus influenzae pneumonia.
Topics: Ampicillin; Animals; Chloramphenicol; Ciprofloxacin; Female; Haemophilus Infections; Haemophilus inf | 1987 |
Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Preclinical; Endocarditis, Bacteria | 1987 |